Résumé
In Europe and North America, the majority of patients diagnosed with cancer are over 65 years of age. This particularly applies to myeloma, a clonal late B-cell disorder, with a median age at diagnosis of 69 years of age. Besides differences in terms of tumor biology, cancer decisionmaking in the elderly is often complicated by the presence of comorbidities and psychosocial factors. We provide a comprehensive review of the epidemiology, biological and clinical features of this disease in elderly patients as well as the diagnostic and treatment strategies that may be implemented in this population.